Skip to main content
editorial
. 2022 Nov 23;29(1):105–109. doi: 10.3350/cmh.2022.0361

Figure 1.

Figure 1.

Three different approaches (i.e., scenarios) to improve risk stratification in the diagnostic grey-zone of clinically significant portal hypertension (CSPH). LSM, liver stiffness measurement; PLT, platelet count; NIT, non-invasive tests; VITRO, ratio of von Willebrand factor and platelet count; SSM, spleen stiffness measurement. *Modified from Dajti et al. (2022) requesting 2 of 3 criteria to exclude CSPH (LSM <15 kPa and PLT ≥150×109/L or SSM ≤40 kPa) and 2 of 3 to rule-in CSPH (LSM ≥25 kPa and PLT <150×109/L or SSM >40 kPa).